RICHELDI, Luca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 18.876
EU - Europa 7.701
AS - Asia 6.421
SA - Sud America 968
AF - Africa 127
OC - Oceania 23
Continente sconosciuto - Info sul continente non disponibili 19
Totale 34.135
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 18.702
GB - Regno Unito 2.738
CN - Cina 2.159
SG - Singapore 1.964
IT - Italia 1.536
HK - Hong Kong 910
SE - Svezia 794
BR - Brasile 780
DE - Germania 565
FI - Finlandia 533
UA - Ucraina 489
VN - Vietnam 342
RU - Federazione Russa 333
TR - Turchia 302
FR - Francia 209
KR - Corea 198
BG - Bulgaria 166
IN - India 137
ID - Indonesia 106
CA - Canada 101
NL - Olanda 81
AR - Argentina 65
MX - Messico 53
ZA - Sudafrica 50
IE - Irlanda 41
BD - Bangladesh 33
EC - Ecuador 33
IQ - Iraq 32
PK - Pakistan 32
JP - Giappone 31
BE - Belgio 30
PL - Polonia 30
AT - Austria 29
IR - Iran 23
ES - Italia 22
UZ - Uzbekistan 21
MY - Malesia 20
NG - Nigeria 20
CO - Colombia 18
AU - Australia 17
AE - Emirati Arabi Uniti 16
PE - Perù 16
PY - Paraguay 16
AL - Albania 14
CL - Cile 14
CH - Svizzera 13
CZ - Repubblica Ceca 13
EU - Europa 13
TW - Taiwan 13
VE - Venezuela 13
LT - Lituania 11
MA - Marocco 11
TH - Thailandia 11
AZ - Azerbaigian 9
DZ - Algeria 9
SA - Arabia Saudita 9
JO - Giordania 8
KE - Kenya 8
DK - Danimarca 7
TN - Tunisia 7
EG - Egitto 6
PT - Portogallo 6
RO - Romania 6
AM - Armenia 5
BO - Bolivia 5
IL - Israele 5
LV - Lettonia 5
OM - Oman 5
UY - Uruguay 5
EE - Estonia 4
GR - Grecia 4
HN - Honduras 4
HR - Croazia 4
KG - Kirghizistan 4
NO - Norvegia 4
NP - Nepal 4
NZ - Nuova Zelanda 4
PA - Panama 4
PH - Filippine 4
A2 - ???statistics.table.value.countryCode.A2??? 3
ET - Etiopia 3
LB - Libano 3
RS - Serbia 3
SK - Slovacchia (Repubblica Slovacca) 3
BZ - Belize 2
CR - Costa Rica 2
DO - Repubblica Dominicana 2
GE - Georgia 2
GY - Guiana 2
JM - Giamaica 2
MG - Madagascar 2
PG - Papua Nuova Guinea 2
PS - Palestinian Territory 2
SN - Senegal 2
XK - ???statistics.table.value.countryCode.XK??? 2
AD - Andorra 1
AF - Afghanistan, Repubblica islamica di 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
Totale 34.106
Salva come PNG Salva come JPEG
Città #
Fairfield 2.178
Southend 2.014
Santa Clara 1.601
Woodbridge 1.472
Ashburn 1.453
Singapore 1.250
Houston 1.143
Jacksonville 959
Chandler 921
Hong Kong 900
Seattle 821
Hefei 804
Dearborn 752
Wilmington 725
Ann Arbor 696
Cambridge 690
Nyköping 452
London 403
Beijing 374
Helsinki 361
Chicago 296
San Jose 271
Los Angeles 258
San Diego 192
Modena 191
The Dalles 179
New York 178
Princeton 172
Sofia 164
Seoul 161
Eugene 158
Council Bluffs 129
Izmir 124
Salt Lake City 118
Buffalo 116
Ho Chi Minh City 110
Milan 94
Shanghai 88
Hanoi 83
Moscow 81
Dallas 70
Jakarta 70
Rome 65
Tampa 62
Naples 60
São Paulo 59
Des Moines 57
Columbus 55
Palermo 51
Redwood City 49
Phoenix 47
Bremen 46
Elk Grove Village 43
Frankfurt am Main 40
Dublin 38
Guangzhou 35
Boardman 34
Sterling 32
Brussels 30
Florence 30
Montreal 29
Norwalk 29
San Francisco 28
Jersey City 27
Atlanta 26
Bari 26
Dong Ket 26
Turin 26
Chennai 25
Warsaw 25
Munich 23
Rio de Janeiro 23
Kunming 22
Boston 21
Detroit 21
Mumbai 21
Orem 21
Kent 20
Lancaster 20
Tashkent 20
Brooklyn 19
Falls Church 19
Miami 19
Philadelphia 19
San Mateo 19
Tokyo 19
Toronto 19
Denver 18
Long Branch 18
Leawood 17
Nanjing 16
Belo Horizonte 15
Haiphong 15
Jinan 15
Mexico City 15
Turku 15
Wuhan 15
Changsha 14
Chengdu 14
Lahore 14
Totale 24.918
Salva come PNG Salva come JPEG
Nome #
Malattie infiltrative diffuse del polmone 1.089
Multidrug-resistant tuberculosis outbreak in an Italian prison: Tolerance of pyrazinamide plus levofloxacin prophylaxis and serial interferon gamma release assays 747
Clinical use of Levofloxacin in the long-term treatment of drug resistant tuberculosis. 429
Non-steroid agents for idiopathic pulmonary fibrosis 403
Bronchoalveolar lavage and response to cyclophosphamide in scleroderma alveolitis. 394
Use in routine clinical practice of two commercial blood tests for diagnosis of infection with Mycobacterium tuberculosis: a prospective study 380
T cell-based tracking of multidrug resistant tuberculosis infection after brief exposure 379
"Velcro-type" crackles predict specific radiologic features of fibrotic interstitial lung disease 366
Performance of tests for latent tuberculosis in different groups of immunocompromised patients 362
T-cell-based diagnosis of neonatal multidrug-resistant latent tuberculosis infection. 346
Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist 339
MDR1 C3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients 338
Diagnosis of occult tuberculosis in hematological malignancy by enumeration of antigen-specific T cells. 330
Atypical lipomatous tumour (lipoma-like well-differentiated liposarcoma) arising in a pulmonary hamartoma and clinically presenting with pneumothorax 319
Levels of circulating endothelial cells are low in idiopathic pulmonary fibrosis and are further reduced by anti-fibrotic treatments 314
Aortic pulse wave velocity measurement in systemic sclerosis patients. 307
A culture-proven case of community-acquired Legionella pneumonia apparently classified as nosocomial: diagnostic and public health implications 301
Room size is the major determinant for tuberculin conversion in health care workers exposed to a multidrug-resistant tuberculosis patient 297
Prior tuberculin skin testing does not boost QuantiFERON-TB results in paediatric contacts 292
Use of Pirfenidone in Idiopathic Pulmonary Fibrosis: A Case Study 288
Role Of The QFT-IT Assay For The Diagnosis Of Latent Tuberculosis Infection Among Adult Immigrants 284
Comparison of the tubercolin skin test and the ellispot blood test for the diagnosis of latent tuberculosis infection in pre-transplant dialysis patients 281
Rifabutin for treating pulmonary tuberculosis. 276
Lung fibrosis, bone marrow fibrosis and liver cirrhosis: A Short Telomere Syndrome or a casual association? 272
Lung cancer in scleroderma: results from an Italian rheumatologic center and review of the literature. 271
A quantitative proteomic approach to identify significantly altered protein networks in the serum of patients with lymphangioleiomyomatosis (LAM) 267
Home Oxygen Saturation Monitoring And Quality Of Life Evaluation In Patients With Idiopathic Pulmonary Fibrosis: Preliminary Results From A Prospective Multicenter Trial 265
Routine hospital use of a new commercial whole blood interferon-gamma assay for the diagnosis of tuberculosis infection 263
Efficacy of hormonal suppression in a patient with chyluria due to lymphangioleiomyomatosis 263
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis 259
New approaches to the design of clinical trials in idiopathic pulmonary fibrosis 259
Novel drug targets for idiopathic pulmonary fibrosis 259
An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias 257
Mindfulness-based stress reduction in patients with interstitial lung diseases: a pilot, single-centre observational study on safety and efficacy 256
Pulmonary fibrosis and the many faces of UIP 256
Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis 255
Macrolides in the treatment of asthma and cystic fibrosis 254
Occurrence of idiopathic pulmonary fibrosis during immunosuppressive treatment: a case report 253
Amyotrophic lateral sclerosis and sarcoidosis: a difficult differential diagnosis. 251
An update on the diagnosis of tuberculosis infection 249
Emerging drugs for idiopathic pulmonary fibrosis. 246
HRCT Patterns Of Usual Interstitial Pneumonia In Rheumatoid Lung 245
Management of Idiopathic Pulmonary Fibrosis 244
An Official ATS/ERS/JRS/ALAT Statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management 243
Quantiferon-TB Gold In-Tube Tests In Hospital Health Care Workers: A Five Years Experience 243
Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis 243
Early diagnosis of subclinical multi drug-resistant tuberculosis 242
Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials 241
Prevalence Of Subclinical Liver Fibrosis Among Patients With Idiopathic Pulmonary Fibrosis 241
Smoking-related interstitial lung disease 239
Triggering receptor expressed on myeloid cells: role in the diagnosis of lung infections 239
Performance of commerical blood tests for the diagnosis of latent tuberculosis infection in children and adolescents 236
Environmental triggers and susceptibility factors in idiopathic granulomatous diseases. 233
Management of idiopathic pulmonary fibrosis. 232
Blood tests for diagnosis of tuberculosis - Reply 228
Sarcoidosis: challenging diagnostic aspects of an old disease. 228
Using ELISpot technology to improve the diagnosis of tuberculosis infection: from the bench to the T-SPOT.TB assay 228
Unexpected identification of bilateral masses in an asymptomatic heavy smoker. 228
Treatment of idiopathic pulmonary fibrosis with ambrisentan: a parallel, randomized trial 226
Acute exacerbations of chronic obstructive pulmonary disease: are antibiotics needed? 224
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. 223
Prevalence and prognosis of unclassifiable interstitial lung disease 222
A multicentre evaluation of the accuracy and performance of IP-10 for the diagnosis of infection with M. tuberculosis 220
The big clinical trials in idiopathic pulmonary fibrosis. 218
Use of a T-cell interferon-γ release assay for the diagnosis of tuberculous pleurisy 216
RHEUMATOID ARTHRITIS RELATED INTERSTITIAL LUNG DISEASE. RADIOLOGICAL PATTERNS AND CORRELATIONS WITH CLINICAL, SEROLOGICAL AND DEMOGRAPHIC FEATURES OF DISEASE 216
Macrolides for chronic asthma. 208
Fibulin-1 predicts disease progression in patients with idiopathic pulmonary fibrosis 208
Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. 208
The complex interrelationships between chronic lung and liver disease: a review. 205
Identification Of Potential Candidate Biomarkers In Lymphangioleiomyomatosis Using ITRAQ Proteomic Technology 205
ANTIBODY REPERTOIRE AGAINST THE A60 ANTIGEN COMPLEX DURING THE COURSE OF PULMONARY TUBERCULOSIS 203
Inappropriatezza prescrittiva dell'ossigenoterapia domiciliare a lungo termine 203
Challenges in idiopathic interstitial lung disease 202
Tubercolosi 201
Immunomodulatory agents for idiopathic pulmonary fibrosis. 199
MOLECULAR DIAGNOSIS OF TUBERCULOSIS 198
Role of the quantiferon-TB test in ruling out pleural tuberculosis: a multi-centre study. 198
HLA-DPB1 Glutamate 69: a genetic marker of beryllium disease 197
Repeated Quantiferon-TB Gold In-Tube Tests In Routine Clinical Practice: A Five Years Experience 197
L'infezione tubercolare nel bambino: il contributo dei nuovi test immunologici 196
Interferon gamma assays for tuberculosis 195
Validation of a Method for Automatic Detection of Lung Sounds in Fibrotic Interstitial Lung Disease 194
Idiopathic pulmonary fibrosis: diagnostic pitfalls and therapeutic challenges. 193
End of an ERA: lessons from negative clinical trials in idiopathic pulmonary fibrosis. 192
Interaction of genetic and exposure factors in the prevalence of berylliosis 190
Tuberculosis infection in foreign-born children: a screening survey based on skin and blood testing. 190
Co-trimoxazole effect on human alveolar macrophages of AIDS patients 190
Genetic testing in diffuse parenchymal lung disease 189
Immunogenetic basis of environmental lung disease: lessons from the berylliosis model 186
Corticosteroid and immunomodulatory agents in idiopathic pulmonary fibrosis 186
The role of biomarkers in low respiratory tract infections. 185
Mycobacterium tuberculosis induces CCL18 expression in human macrophages 185
Tuberculosis diagnostic tests: Sensitivity, specificity, and comparing apples with apples 184
Mapping the future for pulmonary fibrosis: report from the 17th International Colloquium on Lung and Airway Fibrosis 183
Treating idiopathic pulmonary fibrosis: current opportunities and future challenges. 182
Exploring the immune response against Mycobacterium tuberculosis for a better diagnosis of the infection. 181
Idiopathic pulmonary fibrosis: current challenges and future perspectives 179
Levels Of Fibulin-1 In The Lung And Serum Are Increased In Fibrotic Interstitial Lung Disease 179
Pirfenidone in idiopathic pulmonary fibrosis: the CAPACITY program. 178
Totale 25.883
Salva come PNG Salva come JPEG
Categoria #
all - tutte 131.019
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 131.019
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.760 0 0 0 0 0 0 292 444 165 417 243 199
2021/20222.903 86 488 275 221 59 87 200 108 293 208 525 353
2022/20232.694 324 274 169 241 317 402 47 292 331 81 116 100
2023/20242.023 62 129 124 173 372 244 245 244 67 47 128 188
2024/20255.889 212 90 84 417 1.236 847 389 367 631 357 585 674
2025/20266.825 676 489 1.084 1.283 1.747 1.035 511 0 0 0 0 0
Totale 34.334